Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 21
4 123
3 148
2 50
1 23
NEB 6
Curative setting
A 48
C 2
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 3
Breast Cancer 36
Central Nervous System Malignancies 0
Endocrine Tumours 20
Gastrointestinal Cancers 68
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Refractory NTRK fusion-positive cancers 2
Sarcoma 10
Skin Cancers 29
TMB-H solid tumours 1
Thoracic Malignancies 78
Tumor agnostic 2
dMMR/MSI-H solid tumour 1
Curative setting
Brain Tumours 1
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Refractory NTRK fusion-positive cancers 0
Sarcoma 2
Skin Cancers 14
TMB-H solid tumours 0
Thoracic Malignancies 6
Tumor agnostic 0
dMMR/MSI-H solid tumour 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Sorafenib - Placebo Treatment of HCC SHARP
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - SHARP

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    177Lu-PSMA-617 Best standard of care (restricted) Best standard of care (restricted) In combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. VISION
    Genitourinary Cancers
    		 Prostate cancer PSMA-positive mCRPC VISION

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Relatlimab Nivolumab Nivolumab Treatment of adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma RELATIVITY-047
    Skin Cancers
    		 Cutaneous Melanoma - RELATIVITY-047

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Olaparib - Placebo Adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant ChT OlympiA
    Breast Cancer
    		 Early Breast Cancer gBRCAm HER2-negative OlympiA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Pembrolizumab - Single arm Treatment of adults with MSI-H or dMMR unresectable or mCRC after previous fluoropyrimidine-based combination therapy KEYNOTE-164
    Gastrointestinal Cancers
    		 Colorectal Cancer dMMR or MSI-H KEYNOTE-164

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic gastric cancer, who have disease progression on or following at least one prior therapy KEYNOTE-158
    Gastrointestinal Cancers
    		 Gastric Cancer dMMR or MSI-H KEYNOTE-158

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      2
    Pembrolizumab - Single arm cohort study (Phase II) Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic small intestine cancer, who have disease progression on or following at least one prior therapy. KEYNOTE-158
    Gastrointestinal Cancers
    		 Small intestine dMMR or MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study (Phase II) Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic biliary cancer, who have disease progression on or following at least one prior therapy. KEYNOTE-158
    Gastrointestinal Cancers
    		 Biliary tract cancer dMMR or MSI-H KEYNOTE-158

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab Lenvatinib Treatment of physician's choice (doxorubicin or paclitaxel) Patients with advanced or recurrent endometrial carcinoma who have progressed following prior platinum-containing therapy in any setting and who are not candidates for curative surgery or RT KEYNOTE-775
    Gynaecological Malignancies
    		 Endometrial Cancer - KEYNOTE-775

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab Lenvatinib Treatment of physician's choice (doxorubicin or paclitaxel) Patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or RT KEYNOTE-775
    Gynaecological Malignancies
    		 Endometrial Cancer - KEYNOTE-775

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.